Amylyx Pharmaceuticals Crescita futura
Criteri Future verificati 5/6
Amylyx Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 64.2% e 67.1% all'anno. Si prevede che l'EPS crescerà di 65% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -238.1% in 3 anni.
Informazioni chiave
64.2%
Tasso di crescita degli utili
65.05%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 18.8% |
| Tasso di crescita dei ricavi | 67.1% |
| Rendimento futuro del capitale proprio | -238.05% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 18 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Seeking Alpha • Aug 18
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
Summary Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway. Despite a projected cash runway into 2028, company may need to raise capital in 2027; Cash raise possible early as today because of stock trading significantly higher. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 06
AMLX: Q3 LUCIDITY Outcome Will Shape View On Undervalued Opportunity
Amylyx Pharmaceuticals' updated analyst price target of $25.56, up from $24.40, reflects analysts' focus on the upcoming Phase 3 LUCIDITY readout for avexitide in post bariatric hypoglycemia and the related sales potential cited in recent research. Analyst Commentary Recent research on Amylyx Pharmaceuticals centers on the Phase 3 LUCIDITY study of avexitide in post bariatric hypoglycemia, with several firms updating their price targets and framing both upside potential and execution risks around this single pivotal catalyst.Aggiornamento narrativa • Jul 10
AMLX: Phase 3 LUCIDITY Readout Will Drive View On Undervalued Potential
The analyst fair value estimate for Amylyx Pharmaceuticals has been adjusted from $22.20 to $24.40 as analysts reference higher Street price targets, including Guggenheim's move to $40 and the stock's inclusion as a "Best Idea." This is supported by expectations around the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia and the potential of the $6b+ US PBH market. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals focuses heavily on the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia, with valuation views closely tied to how analysts frame the opportunity in the US PBH market and the stock's execution risks around this catalyst.
Aggiornamento narrativa • Jun 26
AMLX: Upcoming PBH Phase 3 Readout Will Drive Bullish Repricing
Amylyx Pharmaceuticals' updated analyst price target has shifted from about $32.63 to roughly $37.58, with analysts citing the stock's inclusion on select "Best Idea" lists and expectations around upcoming LUCIDITY trial results as key reasons for the change. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals highlights a cluster of upbeat views ahead of the LUCIDITY Phase 3 readout for avexitide in post-bariatric hypoglycemia.Nuova narrativa • Apr 02
Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?
Nuova narrativa • Mar 19
Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?Nuova narrativa • Mar 05
PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...Articolo di analisi • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Apr 03
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...Seeking Alpha • Feb 24
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking AlphaArticolo di analisi • Dec 19
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...Articolo di analisi • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Nov 25
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking AlphaArticolo di analisi • Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...Articolo di analisi • Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...Seeking Alpha • Jun 25
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025. The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court. Read the full article on Seeking AlphaPrevisioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 173 | -52 | -37 | -12 | 7 |
| 12/31/2027 | 28 | -172 | -145 | -21 | 10 |
| 12/31/2026 | N/A | -176 | -160 | -152 | 11 |
| 6/30/2026 | N/A | -152 | -131 | -127 | N/A |
| 3/31/2026 | N/A | -150 | -125 | -120 | N/A |
| 12/31/2025 | N/A | -145 | -123 | -123 | N/A |
| 9/30/2025 | -1 | -149 | -155 | -154 | N/A |
| 6/30/2025 | 0 | -188 | -202 | -166 | N/A |
| 3/31/2025 | -1 | -219 | -243 | -207 | N/A |
| 12/31/2024 | 87 | -302 | -204 | -168 | N/A |
| 9/30/2024 | 196 | -259 | -132 | -95 | N/A |
| 6/30/2024 | 299 | -166 | -60 | -59 | N/A |
| 3/31/2024 | 398 | -71 | 15 | 17 | N/A |
| 12/31/2023 | 381 | 49 | 11 | 12 | N/A |
| 9/30/2023 | 294 | 2 | -53 | -51 | N/A |
| 6/30/2023 | 192 | -73 | -91 | -89 | N/A |
| 3/31/2023 | 94 | -149 | -147 | -144 | N/A |
| 12/31/2022 | 22 | -198 | -182 | -180 | N/A |
| 9/30/2022 | 0 | -184 | -161 | -158 | N/A |
| 6/30/2022 | 0 | -153 | -138 | -136 | N/A |
| 3/31/2022 | 0 | -121 | -103 | -103 | N/A |
| 12/31/2021 | 0 | -88 | -75 | -75 | N/A |
| 9/30/2021 | 1 | -68 | -56 | -55 | N/A |
| 12/31/2020 | 1 | -42 | -37 | -37 | N/A |
| 12/31/2019 | 1 | -14 | N/A | -11 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che AMLX diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.7% ).
Guadagni vs Mercato: Si prevede che AMLX diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede AMLX diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di AMLX ( 67.1% all'anno) crescerà più rapidamente del mercato US ( 12.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di AMLX ( 67.1% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che AMLX non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/20 00:00 |
| Prezzo dell'azione a fine giornata | 2026/08/20 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Amylyx Pharmaceuticals, Inc. è coperta da 14 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | Baird |
| Christopher Chen | Baird |
| Joel Beatty | Baird |